Published: Fri, May 19, 2017
Business | By Max Garcia

CytRx Co. (CYTR) Issues Quarterly Earnings Results

Shares of CytRx Corporation (NASDAQ:CYTR) fell $-0.01 during today's regular trading session, a -2.91% decrease from the previous closing price of $0.43. The stock had a trading volume of 15,058,176 shares. CytRx has a 12 month low of $0.36 and a 12 month high of $3.28.

A frequently used metric is a company's price to earnings ratio. While the company's share hit the 52 week high on 05/31/16 stationing the value of $3.28.

CytRx Corporation had its "outperform" rating reiterated by analysts at FBR Capital Markets.

1 analysts on average are expecting CytRx Corporation to report earnings of $-0.5 per share for the current quarter. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. EPS breaks down the profitability of the company on a single share basis.

Basically, a price target is an individual analyst's projection on the future price of a stock. The Higher end of the revenue forecast is $11.42 Million, while the Lower end of the forecast is $11.42 Million. Revenue during that quarter was posted at $0M, whereas the consensus estimate was predicting $0M. Price Target plays a critical role when it comes to the analysis of a Stock.

CytRx Corporation (CYTR)'s distance from 200 day simple moving average is -7.91 percent, its distance from 50 day simple moving average is -4.64 percent, while its distance from 20 day simple moving average is -17.26 percent. It's now trading about -87.18% below its 52-week high. Moving average strategies are also popular and can be tailored to any time frame, suiting both long term investors and short-term traders.

According to Finviz reported data, The SMA20 of the stock is at -16.35 percent, SMA50 is -3.59 percent, while SMA200 is -6.89 percent. For CYTR, the company now has $56.96 Million of cash on the books, which is offset by $5.48 Million current liabilities. The return on assets ratio shows how well management is employing the company's total assets to make a profit.

Headlines about CytRx (NASDAQ:CYTR) have been trending somewhat positive on Thursday, Alpha One reports.

Return on Investment measures the amount of return on an investment relative to the investment's cost. Return on Equity (ROE) stands at -237.7% and Return on Investment (ROI) of -114.4 percent. The stock's market capitalization is $68.93 million. The firm now has a $4.00 target price on the biotechnology company's stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company.

Like this: